Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6081955 | 1.00 | MMP2 (0.36) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Hydrochloric Acid SCHEMBL6079312 | 1.00 | MMP2 (0.36) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Hydrochloric Acid SCHEMBL4426352 | 1.00 | MMP2 (0.36) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL14480001 | 0.98 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL2208895 | 0.98 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL19337855 | 0.98 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL993865 | 0.98 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL993866 | 0.98 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Sulfuric Acid SCHEMBL6078885 | 0.91 | MMP2 (0.33) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Sulfuric Acid SCHEMBL6078882 | 0.91 | MMP2 (0.33) | MMP2ANPEPCHRNB2CHRNA4ABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079801-A | Synthesis method and analysis method of (1S, 4R) -4-amino-2-cyclopentene-1-carboxylic acid methyl ester tartrate | — | 2026-05-26 | — | — | CN | claimed |
| EP-2546242-A1 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2013-01-16 | — | — | EP | claimed |
| CN-122079801-A | Synthesis method and analysis method of (1S, 4R) -4-amino-2-cyclopentene-1-carboxylic acid methyl ester tartrate | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079801-A | Synthesis method and analysis method of (1S, 4R) -4-amino-2-cyclopentene-1-carboxylic acid methyl ester tartrate | — | 2026-05-26 | — | — | CN | disclosed |
| CN-116507610-B | Herbicidal malonamides | 巴斯夫欧洲公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4683908-A1 | SUBSTITUTED OXAZOLIDINONES AND IMIDAZOLINONES AS HERBICIDES | FMC Corporation (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12319664-B2 | Herbicidally active 3-phenylisoxazoline-5-carboxamides of cyclopentenylcarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2025-06-03 | — | — | US | disclosed |
| EP-4251609-B1 | HERBICIDAL MALONAMIDES | BASF SE (DE) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025026808-A1 | HERBICIDAL ALANINE ANALOGUES | BASF SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| EP-4251606-B1 | HERBICIDAL MALONAMIDES | BASF SE (DE) | 2025-01-22 | — | — | EP | disclosed |
| US-12185723-B2 | Herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenylcarboxylic esters | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-07 | — | — | US | disclosed |
| EP-1040094-B1 | SUBSTITUTED CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARM INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF | 2006-11-09 | — | — | US | disclosed |
| US-7038059-B2 | Process for preparation of 4-n-substituted amino-2-aza-1-oxabicyclo[3.3.0] oct-2-ene-6-carboxylic acid esters and process for preparation of their intermediates | KURARAY CO., LTD. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040121482-A1 | Process for preparation of 4-n-substituted amino-2-aza-1-oxabicyclo[3.3.0] oct-2-ene-6-carboxylic acid esters and process for preparation of their intermediates | KURARAY CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1334969-A1 | PROCESS FOR PREPARATION OF 4-N-SUBSTITUTED AMINO-2-AZA-1-OXABICYCLO 3.3.0]OCT-2-ENE-6-CARBOXYLIC ACID ESTERS AND PROCESS FOR PREPARATION OF THEIR INTERMEDIATES | KURARAY CO., LTD. (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6562861-B1 | (1R,3R,4R,1'S)-(-)-(1'-acetylamino-2 '-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50 less-than 1.mu.M). Bactericides or viricides | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-6495711-B2 | 1-(TERT-BUTOXYCARBONYLAMINO)-4-METHOXYCARBONYL-CYCLOPENT-2-ENE STARTING BY REACTING 2-AZABICYCLO(2.2.1)HEPT-5-EN-3-ONE WITH AN ALCOHOL AND NONAQUEOUS ACID; CHEMICAL INTERMEDIATES TO ANTIVIRAL AGENTS AGAINST INFLUENZA VIRUS | BIOCRYST PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020052524-A1 | Process for preparing (-)-(1S, 4R) N-protected 4-amino-2-cyclopentene-1-carboxylate esters | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052524-A1 | Process for preparing (-)-(1S, 4R) N-protected 4-amino-2-cyclopentene-1-carboxylate esters | CPNE4, PYM1, CCNT1 | CHRNB4 614/4885CHRNA3 1247/4885CHRNA7 846/4885 |
| US-12319664-B2 | Herbicidally active 3-phenylisoxazoline-5-carboxamides of cyclopentenylcarboxylic acid derivatives | AADAC, PRDX5, DDT | CHRNB4 3822/4885CHRNA3 1742/4885CHRNA7 884/4885 |
| US-12185723-B2 | Herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenylcarboxylic esters | NOTUM, AADAC, DDT | CHRNB4 4413/4885CHRNA3 2282/4885CHRNA7 2081/4885 |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, ALDH18A1 | CHRNB4 3570/4885CHRNA3 4159/4885CHRNA7 3707/4885 |
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | ADCY5, ADCY6, ADCY2 | CHRNB4 82/4885CHRNA3 77/4885CHRNA7 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.